LIB Therapeutics

China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB Therapeutics Inc., securing the development and commercial rights to LIB’s lerodalcibep for the Greater China territory, which includes mainland China, Hong Kong, Macau, and Taiwan. The agreement involves an upfront payment of USD 20 million…